Skyscape Web Viewer : The Maudsley Prescribing Guidelines in Psychiatry : Main Index

View All
Psychotic symptoms
Psychotropic drug groups in hepatic impairment
Psychotropic drug risks
Psychotropic drugs driving impairment in overdose interactions with illicit drugs plasma level monitoring smokers steady state target ranges use in renal impairment with alcohol
Psychotropic drugs: choice in patients who continue to drink
Psychotropic drugs in overdose
Psychotropic drug starting doses
Psychotropic medications approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), European Medicines Agency and the US Food and Drug Administration for children and adolescents (January 2024)
Psychotropics and driving
Psychotropics in epilepsy
Pure red cell aplasia, psychotropic agent effects
Pyridoxine, for tardive dyskinesia
QTc prolongation antipsychotic-related cardiovascular risk factors ECG monitoring management metabolic inhibition methadone risk non-psychotropic association patients psychotropic-related risk factors QT interval risk factors risk quantification switching antipsychotics
Quercetin
Questionnaires adherence assessment severity of alcohol dependence
Quetiapine acute kidney injury risk bipolar disorder borderline personality disorder glucose tolerance impairment association in overdose plasma level monitoring rapid-cycling bipolar affective disorder risks in pregnancy target range thyroid function tests weight restoration in anorexia nervosa
Raloxifene Alternatives to clozapine Menopause
Randomised controlled trials (RCTs) of the use of long-acting injections (LAIs) in bipolar affective disorder
Rapid-cycling bipolar affective disorder Rapid-cycling bipolar affective disorder Switching antipsychotics
Rapid cycling type Rapid-cycling bipolar affective disorder Valproate
rapid tranquilisation (RT) 62 Acutely disturbed or violent behaviour children and adolescents physical monitoring remedial measures site of administration of intramuscular injections
Rapid tranquillisation
Rating of Medication Influences (ROMI) scale
Readiness to change, influencing adherence
Recommendations for delayed maintenance dose of Ari 2MRTU
Recommendations for treatment for depression in multiple sclerosis (MS)
Recommendations for treatment of depression in Parkinson's disease (PD)
Recommendations for treatment of psychosis in Parkinson's disease (PD)
Recommendations for using psychotropics in atrial fibrillation (AF)
Recommendations to patients, adherence